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Introduction
The role of viral infections in the pathogenesis of SLE and
other autoimmune diseases has long been debated.
Herpesviruses such as Epstein–Barr virus (EBV) and CMV
have been of particular interest because of their ability to
interact with the immune system in a variety of ways, as
well as their ability to establish latency with the potential for
reactivation. Both human and murine CMV infections have
been associated with autoimmunity [1–10].
CMV can be transmitted in utero with both primary and
reactivated maternal infections, a feature that accounts for
the inordinately higher incidence of congenital CMV infec-
tion than of other intrauterine viral infections [11]. About
30,000–35,000 US infants (1% of live births) are born
annually with congenital CMV infection [11]. Neonatal CMV
infection is one of the leading causes of mental retardation
[12]. Vaccination of young women of childbearing age is a
logical approach to preventing neonatal CMV infections.
The major envelope glycoprotein of CMV, referred to as
gB (also known as gpUL55), has been the primary focus
of subunit vaccine studies because of its strong immuno-
genicity [13–19]. This protein is conserved throughout the
herpesviruses [20,21], plays a role in cell entry and cell-to-
cell dissemination [22], and may also determine cell
tropism [23]. There appear to be at least two cell-surface
receptors for gB, including heparan sulfate proteoglycans
[24]. Interestingly, gB also binds to annexin II [25], a
phospholipid-binding protein, which is located intra-
cellularly, although cell-surface and secreted forms of
annexin II have been identified [26], and this interaction
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may account for CMV-induced anti-phospholipid antibod-
ies [7,27]. Additional viral proteins and coreceptors are
required for CMV penetration and fusion [28].
The complexes of U small nuclear RNAs (U snRNAs) and
their associated proteins are highly conserved and are
essential for the splicing of precursor messenger RNAs.
Almost all U1 snRNP proteins are targets of autoantibod-
ies (for review [29]). The antibody response to snRNP
gives a speckled immunofluorescence pattern and targets
the proteins U1-70k, U1-A, and U1-C, which are uniquely
associated with the U1 snRNA, with the predominant
response being to the U1-70k protein [29]. In previous
studies, we found that intraperitoneal injections of an ade-
novirus recombinant expressing CMV gB (Ad-gB) induced
IgG autoantibody responses to the U1-70k spliceosome
protein in both autoimmune and normal mouse strains [3].
Similar autoantibodies are typically detected in patients
with SLE and mixed connective-tissue disease (MCTD).
While anti-U1 snRNP autoantibodies are found in patients
with MCTD and SLE, antibodies to ribonucleoproteins
recognized by antibodies from a patient named Smith
(Sm), which react with the B¢/B, and D proteins as well as
with the E–F–G complex (the common core proteins of
U1 snRNP and other U snRNPs) [29,30], are detected
mainly in patients with SLE (in 20–30% of such patients).
Antibodies to U1 snRNP in the absence of anti-Sm are
found in <10% such patients [30]. In MCTD, the antibody
response to Sm is rare [31,32].
In the present study, we investigated anti-RNP and anti-Sm
responses in adults with and without CMV infection as
defined by antibody status. In addition, we characterized the
CMV antibody response in patients with autoimmune dis-
eases. The results suggest an association between CMV
seropositivity and the immune response to U1 snRNP.
Methods
Subjects
Anonymously coded specimens of serum from 100
healthy individuals (80 females), aged 18–50 years (98
whites, 1 Asian, and 1 African American) were obtained
from the University of Louisville. These individuals, none
with symptoms of acute CMV infection, had been
screened for participation in various vaccine studies, and
thus those that were positive for anti-CMV antibodies
would be classified as latently infected. Sera from 40
patients fulfilling the criteria for SLE [33] were kindly sup-
plied by Dr Paul Fortin and Dr Ann Clarke, at the Lupus
Clinic, the Montreal General Hospital. Half of these sera
were either Sm/RNP-positive or -negative as previously
determined by enzyme-linked immunosorbent assay
(ELISA) (Inova Diagnostics, San Diego, CA, USA). Sera
from patients fulfilling criteria for MCTD, dermatomyositis,
or polymyositis were obtained from clinics of the medical
school at the University of Nijmegen, The Netherlands.
Detection of anti-CMV antibodies
Total CMV-specific IgG was measured by ELISA
(Cytomegalovirus IgG ELISA Kit; INCSTAR Corp., Still-
water, MN, USA). IgG antibodies to gB were measured
by ELISA using a modified gB protein containing the
major linear neutralizing domains AD-1 [34] and AD-2
[35] but lacking heavily glycosylated intervening regions
and transmembrane and cytoplasmic domains [36]. This
construct was used because it was available. This
protein was expressed in insect cells by recombinant bac-
ulovirus to preserve co- and post-translational modifica-
tions. Briefly, 96-well plates (Corning Costar, Kennebunk,
ME, USA) were coated with clarified baculovirus-
infected cell lysates diluted 1:2000 in phosphate-
buffered saline solution (PBS; 50 µl/well) and then
blocked with 1% bovine serum albumin. Sera were
diluted in buffer consisting of 0.05% Tween-20 and
0.25% bovine serum albumin in PBS and incubated in
the antigen-coated wells for 1 h. After being washed,
bound antibody was detected by horseradish-peroxi-
dase-conjugated goat anti-human IgG (Biosource
International, Camarillo, CA, USA) diluted 1:750 in
PBS/0.05% Tween-20 (2 h incubation) and conversion
of 2,2¢-amino-bis(3-ethylbenzthiazoline)-6-sulfonic acid
as measured by optical density (OD) at 405 nm. Each
serum specimen was assayed in two wells containing
recombinant baculovirus-infected cell antigens and two
wells containing antigens from cells infected with
parental baculovirus. Specimen OD was taken as the
difference between the average gB signal and the
average background signal. AD-1- and AD-2-specific
monoclonal antibodies were reactive in this assay.
Samples were considered positive if they were above
the cut-off of 0.4, which was the mean OD +3 SD from
332 CMV-seronegative sera. Sera were routinely tested
at 1:100 dilution and the resultant OD was used as a
quantitative measure of antibody to gB epitopes.
Detection of antibodies against Sm, RNP, or U1-70k
ELISAs were used to detect anti-Sm or anti-RNP IgG
response as previously described [3]. The target antigen
was calf-thymus Sm or RNP (Immunovision, Springdale,
AZ, USA). Antibodies specific for the amino-terminal frag-
ment of recombinant U1-70k protein were also measured
by ELISA as previously described [3]. For these assays,
internal standards allowed the comparisons between
ELISA plates. Because we were measuring the levels of
autoantibodies in normal individuals, the cutoff value was
the mean + 2 SD found in 15 normal individuals known to
be CMV-antibody-negative from a pilot study, rather than
unselected normal individuals. However, the CMV status
of the normal individuals in this study was not known prior
to the analysis. The data were also analyzed using a cutoff
value of the mean +3 SD for this cohort of 100 individuals.
Sera that were positive at a 1:200 dilution were serially
diluted to 1:8000 in order to determine the antibody titers.c
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Immunoblot analysis
To determine the specificity of the U1 snRNP autoantibod-
ies in high-titer responders, purified calf-thymus Sm and
RNP (ImmunoVision) were used as substrate. Purified
Sm/RNP proteins, 1.5 mg per lane, were resolved on 10%
SDS–acrylamide gels [37]. The proteins were transferred
to nitrocellulose strips (Micron Separations Inc., Westbor-
ough, MA, USA) as previously described [38]. Following
transfer, the strips were blocked for 1 h in PBS–Tween
and then incubated with selected sera diluted 1:2000 in
PBS–Tween for 2 h at 37°C. After three washes with
PBS–Tween, the strips were incubated for 1 h at 37°C
with horseradish-peroxidase-conjugated F(ab¢)2 fragments
of anti-human IgG diluted 1:15,000 (Jackson ImmunoRe-
search, West Grove, PA). After this incubation, the strips
were washed five times with PBS–Tween, and bound anti-
bodies were detected using a chemiluminescence sub-
strate according to the manufacturer’s instructions
(Western Blot Chemiluminescence Reagent, NEN,
Boston, MA, USA). The strips were exposed to Biomax
MR Film (Kodak, Rochester, NY, USA).
Statistics
The statistical tests used included linear regression analy-
sis, c2 analysis, and Fisher’s t-test, as appropriate.
Results
Table 1 shows antibody responses to RNP, Sm, and
U1-70k among healthy adults with and without CMV
infection. There was a highly significant association
between CMV infection and the presence and level of
such autoantibodies. There was, however, no linear corre-
lation between antibodies to RNP, Sm, or U1-70k and
antibodies to the modified gB molecule that contains AD-
1 and AD-2 but lacks the heavily glycosylated portion and
is truncated at amino acid 646 (r = 0.029 for antibodies
to RNP versus gB; r = 0.006 for antibodies to Sm versus
gB; r = 0.029 for antibodies to U1-70k versus gB). This
suggests that the putative site of mimicry is not present in
this molecule.
Compared to the usual methods of assigning a cutoff
value from unselected normal individuals, the cutoff used
for autoantibodies in this study is lower, based on a pilot
study. This allowed us to discriminate within the normal
group. Thus the apparent proportion of positive sera at a
dilution of 1:200 (Table 1) is higher than that previously
reported. As can be seen in Table 1, the mean OD of
autoantibody responses is significantly higher in individu-
als who have anti-CMV antibodies. Autoantibodies to the
U1 snRNP proteins, however, were also detected in a
subset of CMV-negative individuals. When the data were
analyzed with the cutoff value of the mean +3 SD, 8 sera
were positive for antibodies to U1-70k, with 7/8 CMV-
positive and 1/8 CMV-negative. Of the 100 sera, 5 were
positive for antibodies to RNP with the more stringent
cutoff value, and all 5 were CMV-positive. For Sm, 10 of
100 were positive for antibodies to Sm when the cutoff
value was the mean +3 SD, with 7/10 CMV-positive and
3/10 CMV-negative.
Anti-Sm/RNP titers were also examined in this group of
normal individuals. Of the 100 healthy individuals tested,
18 had a high-titer response to Sm/RNP of greater than
1:1000, which was analogous to that seen in the SLE
patients tested. Thirteen of these individuals were CMV-
antibody-positive (10 females, 3 males) and 5 were CMV-
antibody-negative (2 females, 3 males). In one patient for
whom serum was available before and after CMV infec-
tion, only the postinfection serum was positive for IgM
anti-Sm/RNP autoantibodies when tested by ELISA and a
standard Ouchterlony immunodiffusion technique (data
not shown). Of the normal individuals tested with autoanti-
bodies to the spliceosome components (when using the
mean plus 2 SD cutoff), 7 individuals were positive for
antibodies to the spliceosome in all three assays, 5 had
positive results in two assays, and 21 had only one one
positive autoantibody assay (15 of the 21 were positive for
U1-70k only). In contrast, of the SLE patients who had
positive tests for the anti-spliceosome antibody, 18 of 23
had positive results in all three assays.
Available online http://arthritis-research.com/content/3/4/253
Table 1
Autoantibodies associated with CMV serostatus in healthy adults
Autoantibody CMV-positive group (n = 50) CMV-negative group (n = 50)  P value
RNP
No. positive (%)a 42 (84) 12 (24) <0.0001
Mean OD±SD 0.643±0.187 0.406 ± 0.162 <0.0001
Sm
No. positive (%)a 32 (64) 18 (36) 0.002
Mean OD±SD 0.712 ± 0.484 0.505 ± 0.413 0.002
U1-70kb
No. positive (%)a 23 (46) 10 (20) 0.01
Mean OD±SD 0.921 ± 0.216 0.698 ± 0.235 <0.0001
aBased on mean + 2 SD. bAmino-terminal fragment.We measured the total serum IgG levels by ELISA [3] in
the autoantibody-positive versus antibody-negative and
found that the mean levels were not significantly different
(15.42 ± 5.27 and 15.54 ± 7.25 mg/ml, respectively). Sur-
prisingly, the individuals with the high-titer response to
Sm/RNP had a mean IgG of 14.73 ± 5.00 mg/ml, sug-
gesting that polyclonal activation was not responsible for
the detection of the high titer. The mean serum IgG con-
centrations in the CMV-antibody-positive and -negative
individuals were 16.56 ± 7.30 and 14.32 ± 4.9 mg/ml,
respectively, which were not significantly different.
Simple linear regression analyses in the cohort of 100
healthy individuals (both CMV-positive and -negative) indi-
cated r = 0.566 (P < 0.0001) for the anti-RNP versus anti-
Sm response; r = 0.559 (P < 0.0001) for the anti-RNP
versus anti-U1-70k response, and r = 0.317 (P = 0.0013)
for the anti-Sm versus anti-U1-70k response, indicating
high correlations. The relatively low r values indicate the
complexity of these immune responses and the multiplicity
of proteins (and epitopes) in the spliceosome that are tar-
geted. This complexity is illustrated in Figure 1: antibodies
from both the SLE sera and normal sera target multiple
proteins in the Sm and RNP preparations. However, the
predominant response was toward the U1-70k protein.
Having observed an association between CMV antibody
positivity and autoimmune responses to the U1 snRNP
proteins, we were interested in determining the CMV-anti-
body status of patients with autoimmune disease who
have antibodies to Sm/RNP. There was an excellent corre-
lation between the assay used in the present study and
the prior autoantibody status as determined by the Quanti-
Lite ELISA (Inova Diagnostics; data not shown). As can be
seen in Table 2, about 60% of the patients with disease
had antibodies to CMV, a proportion similar to that found
in the general population [12]. The MCTD group had a
CMV-antibody frequency of about 40%, which is low. In
the SLE group only, there was a significant association
between CMV status as measured by circulating IgG anti-
bodies and the anti-RNP response. The lower P value for
this group than in the healthy controls may reflect in part
the smaller size of the group. Analysis of the immunoblots
showed that there was a more diverse antibody response
to the Sm/RNP proteins in the SLE sera than in the normal
individuals (Fig. 1, and data not shown).
Discussion
We have found an association between autoimmune
responses to the U1-70k protein and CMV infection, both
in normal individuals and in patients with SLE. The fre-
quency of antibody to U1-70k has been reported to be
30–40% in patients with SLE [30], and 90–100% in
patients with MCTD, where anti-snRNP is a diagnostic cri-
terion (for review [30]). The frequency of the presence of
this antibody in African Americans and Asians is about
twice that in whites [39]. Since both the cohorts of normal
individuals and SLE patients were about 98% white, this
ethnic difference in phenotypic response does not compli-
cate the analysis of our data.
There have been only limited reports of the frequency of
autoantibodies to anti-Sm/RNP, in small groups of the
general population. The reported frequencies range from
0–10% [39,40]. In our cohort of normal individuals, 
the frequencies of high-titer (>1/1000) anti-Sm/RNP
responses were 26% in the CMV-positive group and 10%
in the CMV-negative group (18% overall). Neither of the
Asian nor African American individuals was in the high-
titer-responder group. These high-titer sera were positive
against Sm, RNP, and recombinant U1-70k in ELISA and
Arthritis Research    Vol 3 No 4 Newkirk et al
Figure 1
Antibodies from SLE and normal sera from CMV-antibody-positive and
-negative individuals target primarily the U1-70k protein in the
spliceosome as determined by immunoblot analysis. Lane 1, second
antibody control; lanes 2 and 3, SLE sera; lanes 4–11, sera from
normal individuals. Sm proteins A, B¢/B, and C are designated on the
left. Molecular-weight markers are designated on the right. All sera
were diluted 1/2000. *As determined by ELISA.
Table 2
CMV serostatus of patients with autoimmune disease
Patient‘s
CMV-positive
diagnosis Autoantibody % No./no. tested P
SLE Sm+ 63 12/19
Sm– 57 12/21 ns
RNP+ 74 17/23
RNP– 41 7/17 0.05
MCTD Sm+ 50 1/2 
Sm– 35 6/17 ns
RNP+ 37 7/19
DM/PM NA* 60 9/15
*Not available. DM, dermatomyositis, ns, not significant, PM,
polymyositis.also against U1-70k in immunoblots and appeared more
SLE-like than MCTD-like in their reactivity.
The U1-70k protein is often the first U1 snRNP protein to
which autoantibodies develop in serially followed patients
with SLE [41], and this appeared to be the most common
‘solo’ autoantigen in the normal individuals targeted. In a
study of autoantibodies in sera that predate the diagnosis
of SLE, antibodies to Sm and RNP can be detected in
approximately 40% up to 8 years before diagnosis [42].
Thus, it is possible that some of these normal individuals
with high-titer anti-Sm/RNP responses, who have a
genetic susceptibility for autoimmunity, may develop SLE
over time. It is intriguing to think that with periodic reacti-
vation of CMV, this autoantibody response could be
boosted, and such individuals may be at risk of developing
SLE in a shorter period of time than those that have the
anti-U1-70k response in the absence of CMV infection.
However, we cannot rule out other herpesviruses (such as
herpesvirus 6 and 7 [20,21]), which have highly homolo-
gous gB proteins (approximately 26% amino acid identity,
with 45% homology at the protein level and 70% at the
nucleotide level), from having a role in the development of
this autoimmune response. These viruses can also cause
latent infections and periodically reactivate.
From our murine studies, molecular mimicry may be
responsible for the induction of the autoimmune response
[3]. The autoimmunogenic epitope in gB is likely to be
located between amino acids 700 and 907 (Newkirk,
manuscript in preparation), where there are similarly
charged amino acids to the carboxy terminal region of
U1-70k. The region 700–907 was not present in the mod-
ified gB molecule used in the current study.
We found that approximately 60% of the adult SLE
patients had evidence of anti-CMV antibodies, which is
similar to the frequency of infection seen in the general
population. Previous reports have varied from 42–90%
(teenage to adult) [43,44]. In contrast, in the small group
of patients with MCTD, there was no discernible correla-
tion with CMV infection. This latter finding, however, does
not rule out a role for the gB from other herpesviruses in
the induction of an anti-RNP response in MCTD.
Disease features that are significantly increased in SLE
patients that have circulating autoantibodies to Sm and /or
RNP when compared to SLE patients lacking these
autoantibodies include: Raynaud’s phenomenon, arthritis,
and mean number of nail fold capillary loops [45]. In addi-
tion, anti-Sm/RNP antibodies have been linked to late-
onset renal disease [46]. Thus, these autoantibodies
appear to define a distinct clinical and serological subset
of SLE patients. Since antibodies to Sm/RNP can
precede the disease for many years [42], their precise role
in the pathogenesis is unclear. It is likely, however, that
autoreactive B cells could contribute to the spreading of
the immune response to other epitopes or determinants by
aiding in the endocytosis and presentation of linked
autoantigens, in a genetically susceptible host. The data
presented here suggest that studies of gB subunit vac-
cines in humans should include assays for the analysis of
possible autoantibodies after vaccination.
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